1、Vertex Reports First Quarter 2025 Financial ResultsMay 5,2025 Total revenue of$2.77 billion,a 3%increase compared to Q1 2024;raised the low end of total revenue guidance by$100 million to a new range of$11.85 to$12 billion Strong progress with CASGEVY,ALYFTREK and JOURNAVX launches Povetacicept(pove

2、)IgAN Phase 3 interim analysis(IA)cohort fully enrolled and zimislecel Phase 3 program to complete dosing this quarter,settingup potential filings in 2026;inaxaplin Phase 3 IA cohort on track to complete enrollment in the second half of 2025 Four programs already in pivotal development,with pivotal

3、study of pove in primary membranous nephropathy(pMN)to start this year BOSTON-(BUSINESS WIRE)-May 5,2025-Vertex Pharmaceuticals Incorporated(Nasdaq:VRTX)today reported consolidated financial results forthe first quarter ended March 31,2025,and raised the low end of its total revenue guidance range b

4、y$100 million,from$11.75 billion to$12 billion to anew range of$11.85 billion to$12 billion.“Vertex delivered a strong start to 2025 with notable execution across the business as we grow and diversify the revenue base,progress multiplelaunches and advance the R&D pipeline.We continued to expand our

5、leadership in CF and build global momentum for CASGEVY,and we launchedJOURNAVX in moderate-to-severe acute pain,”said Reshma Kewalramani,M.D.,Chief Executive Officer and President of Vertex.“With multipleprograms in pivotal development including povetacicept,which continues to make rapid progress in

6、 achieving its potential as a pipeline-in-a-product,and additional programs in early and mid-stage development,Vertex is poised to continue to deliver value for years to come.”First Quarter 2025 ResultsTotal revenue increased 3%to$2.77 billion compared to the first quarter of 2024,primarily driven b